BMS-986251

DB19007InvestigationalSmall molecule

BMS-986251 is under investigation in clinical trial NCT03329885 (A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis).

Formula / weight: C₃₀H₂₉F₈NO₅S · 667.61 g/mol (avg)
Also known as: (1R,3S,4R)-4-((3AR,9BR)-9B-((4-FLUOROPHENYL)SULFONYL)-7-(PERFLUOROPROPAN-2-YL)-2,3,3A,4,5,9B-HEXAHYDRO-1H-BENZO(E)INDOLE-3-CARBONYL)-3-METHYLCYCLOHEXANE-1-CARBOXYLIC ACID
Code names: BMS-986251

Resolves to

Compound

UNII2WQX2MS3MQCAS2041841-30-7ChEMBLCHEMBL4634542

Structure

InChIKeyJQORWGARJVSRBA-QOTTZFGFSA-NSMILES[H][C@@]12CCC3=CC(=CC=C3[C@@]1(CCN2C(=O)[C@@H]1CC[C@H](C[C@@H]1C)C(O)=O)S(=O)(=O)C1=CC=C(F)C=C1)C(F)(C(F)(F)F)C(F)(F)F

What you can answer from here — as of June 29, 2024

1Clinical trialPhase, status and sponsor resolved per trial

Which companies are running trials of BMS-986251, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account